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The accumulation of plasma advanced oxidation protein
products (AOPPs) is prevalent in chronic kidney disease. We
previously showed that accumulation of AOPPs resulted in
podocyte apoptosis and their deletion by a cascade of
signaling events coupled with intracellular oxidative stress.
The transmembrane receptor that specifically transmits
the AOPPs’ signals to elicit cellular activity, however,
remains unknown. Using co-immunoprecipitation and
immunofluorescence, we found that AOPPs colocalized and
interacted with the receptor of advanced glycation end
products (RAGE) on podocytes. Blocking RAGE by anti-RAGE
immunoglobulin G or its silencing by siRNA significantly
protected podocytes from AOPPs-induced apoptosis both
in vitro and in vivo and ameliorated albuminuria in AOPPs-
challenged mice. AOPPs-induced activation of nicotinamide
adenine dinucleotide phosphate oxidase and the excessive
generation of intracellular superoxide were largely inhibited
by anti-RAGE immunoglobulin G or RAGE siRNA. Moreover,
blockade of RAGE decreased the activation of the p53/Bax/
caspase-dependent proapoptotic pathway induced by
AOPPs. Thus, AOPPs interact with RAGE to induce podocyte
apoptosis and this, in part, may contribute to the progression
of chronic kidney disease.
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Chronic kidney disease (CKD) is a worldwide health
problem, and the population of CKD patients is increasing
rapidly.1 The pathogenesis of CKD is characterized by
widespread glomerulosclerosis and interstitial fibrosis. There
is a growing body of literatures showing that podocyte loss is
related to the increased proteinuria and contributes to the
renal progression in both diabetic and nondiabetic CKD.2–8
Therefore, exploring factors implicated in the pathogenesis of
podocyte injury is of great importance to the development of
new strategies for the treatment of CKD.
AOPPs are a family of oxidized, dityrosine-containing
protein products generated during excessive production of
oxidants and often carried by albumin in vivo.9,10 Accumula-
tion of plasma AOPPs was first found in patients under-
going dialysis9 and subsequently demonstrated in patients
with diabetes11,12 and metabolic syndrome.13 Clinical studies
have shown that AOPPs level is a strong predictor for the
prognosis of immunoglobulin-A nephropathy.14 In experi-
mental models, chronic accumulation of plasma AOPPs is
associated with aggravated glomerulosclerosis in remnant
kidney and diabetic nephropathy.15,16 These data indicate
that AOPPs may not merely be a marker for oxidative
stress, they are actually a new class of renal pathogenic
mediators as well.9,14
Most recently, we demonstrated that AOPPs induce
podocyte apoptosis and deletion via the nicotinamide
adenine dinucleotide phosphate (NADPH) oxidase-depen-
dent, Rodox-sensitive signaling, for the first time, establish-
ing a causative link between oxidative stress and podocyte
loss. However, the transmembrane receptor that specifically
transmits the signal of AOPPs to elicit cellular activity has not
yet been addressed. Previous studies have shown that various
scavenger receptors (SRs) such as RAGE (receptor of
advanced glycation end products), SR class A, and CD36
are expressed on the surface of podocytes.17–19 Marsche
et al.20,21 and our group have shown that class B type I
receptor (SR-BI) and RAGE mediate AOPP-induced inflam-
matory response in endothelial cells.20–22 Thus, the present
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study was aimed to characterize the receptor responsible for
AOPPs-induced podocytes apoptosis.
RESULTS
RAGE mediated AOPPs-induced apoptosis in cultured
podocytes
To clarify which receptor on podocyte is responsible for
AOPPs-induced podocyte apoptosis, we preincubated podo-
cytes with various concentrations of anti-RAGE, anti-CD36,
anti-SR class A, anti-LOX1, anti-AGE-R3, anti-SR-BI or
anti-TLR4 antibody before AOPPs exposure. As shown in
Figure 1a and b, Supplementary Figures S1 and S2 online,
only anti-RAGE significantly blocked AOPPs-induced podo-
cyte apoptosis. Preincubation with anti-RAGE antibody
significantly abrogated the apoptotic effect of AOPPs in a
dose-dependent manner with 70% reduction at 20mg/ml
concentration, whereas 20mg/ml of nonimmune immunoglo-
bulin G (IgG) had no detectable effect.
To further confirm the role of RAGE on AOPPs-induced
podocyte apoptosis, we next knocked down endogenous
RAGE expression using a RAGE-specific small interference
RNA (siRNA). As shown in Figure 1c, RAGE siRNA reduced
the RAGE protein expression by 60–70%. We then transfected
RAGE siRNA or scramble siRNA into podocytes before AOPPs
treatment. Flow cytometric analysis showed that RAGE-
specific siRNA transfection resulted in a significant decrease
in AOPPs-induced apoptosis as compared with scramble
siRNA transfection (Figure 1d and Supplementary Figure S3
online). Similar result was obtained using terminal deoxyur-
idine nick-end labeling staining (TUNEL; (Figure 1e)).
To test whether AOPPs interact with RAGE on podocyte,
we performed co-immunoprecipitation assay. As shown in
Figure 1f, AOPPs were detected by anti-AOPPs antibody in
the anti-RAGE immunoprecipitate in AOPPs-treated cells but
not in control cells. The colocalization of AOPPs and RAGE
on podocyte was further confirmed by co-immunofluores-
cence staining in AOPPs-treated cells (Figure 1g).
RAGE mediated AOPPs-induced intracellular superoxide
generation in vitro
Our previous study has demonstrated that NAD(P)H
oxidase-dependent O2
 production is the key step of
AOPPs-induced podocyte apoptosis. We thus examined
whether this key step is mediated by RAGE. As shown in
Figure 2a, AOPPs-induced O2
 production could be blocked
by both anti-RAGE antibody and RAGE siRNA transfection.
Similarly, AOPPs-induced activation of NAD(P)H oxidase,
such as p47phox phosphorylation, binding of p47phox with
p22phox, and the expression of NADPH subunits p47phox and
gp91phox, could be inhibited by blocking RAGE using either
anti-RAGE IgG or RAGE siRNA transfection (Figures 2b and c).
We previously demonstrated that AOPPs-induced
NADPH oxidase-dependent O2
 production could be blocked
by total protein kinase C (PKC) inhibitor,23 suggesting that
PKC activation is the upstream event of NADPH oxidase
activation. However, which isoform of PKC is responsible for
this effect remains unclear. Therefore, we tested the effect of
AOPPs on the phosphorylation of the main subunits of PKC
such as PKCa, PKCb1, PKCb2, and PKCz. As shown in
Figure 3a and b, AOPPs exposure significantly increased the
phosphorylation of PKCa (Po0.01), but had no effect on the
phosphorylation of PKCb1, PKCb2, and PKCz.
To test whether the activation of PKCa is mediated by
RAGE, we pretreated podocytes with anti-RAGE or RAGE
siRNA transfection before AOPPs exposure. As shown in
Figure 3c and d, blocking RAGE dramatically attenuated
AOPPs-induced PKCa phosphorylation, indicating that the
effect of AOPPs on PKCa activation is mediated by RAGE.
RAGE mediated AOPPs-induced activation of
p53/Bax/caspase-3 pathway in vitro
We previously demonstrated that AOPPS-induced podocyte
apoptosis is associated with increased activity of the p53/Bax/
caspase-3 pathway. To examine whether AOPPS-induced
activation of p53/Bax/caspase-3 pathway was RAGE depen-
dent, we preincubated podocytes with anti-RAGE antibody
or nonimmune IgG before AOPPs exposure. As shown in
Figure 4a, AOPPs-enhanced expression of p53 and Bax
proteins was dramatically inhibited by anti-RAGE antibody.
Similar result was obtained when podocytes were transfected
with specific RAGE siRNA (Figure 4b).
Similarly, AOPPs challenge resulted in increased cleaved
caspase-3 followed by decrease in procaspase-3. The levels of
intact 113-kDa poly (adenosine diphosphate-ribose) polymer-
ase (PARP), a substrate of activated caspases, were decreased
after AOPPs treatment, coincident with the appearance of 85-
kDa PARP cleavage products (Figure 4c and d). AOPPs-
enhanced expression of cleaved caspase-3 and PARP (85 kDa)
could be blocked by anti-RAGE antibody or RAGE siRNA
(Figure 4c and d), suggesting that AOPPs-induced activation
of proapoptotic pathway is mainly mediated by RAGE.
AOPPs enhanced RAGE expression on podocyte in vitro and
in vivo
Previous studies have shown that RAGE expression is linked
to the situations in which its ligands are abundant.24,25 We
therefore examined the effect of AOPPs on RAGE expression
in podoctyes. Podocytes were treated with indicated con-
centrations of AOPPs for 12 h. As shown in Figure 5a–d,
AOPPs challenge significantly augmented RAGE expression
in cultured podocytes at both mRNA and protein levels in a
dose- and time-dependent manner.
To determine whether AOPPs could induce RAGE expres-
sion in vivo, normal C57BL/6 mice were administrated with
intravenous injection of AOPPs modified mouse serum
albumin (AOPPs-MSA) for 5 weeks. We first examined the
effect of AOPPs on RAGE expression by western blot. As
shown in Figure 5e, RAGE expression was significantly
increased in AOPPs-challenged mice compared with control
mice. We next examined the localization of RAGE using
immunohistochemistry staining. Co-staining of RAGE with
antibody against podocyte marker Wilms’s tumor-1 indicated
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Figure 1 |AOPPs-induced podocyte apoptosis is RAGE-dependent. Mouse podocytes were treated with indicated amount of RAGE
neutralizing antibody (a) or indicated neutralizing antibody (b) followed by AOPPs treatment for 24 h. Cells treated with medium alone
(control, Ctrl) or unmodified mouse serum albumin (MSA) were served as controls. Podocytes apoptosis was analyzed by flow cytometry.
(c) Podocytes were transfected with RAGE siRNA or scramble siRNA. Western blot was performed to analyze the expression of endogenous
RAGE in podocytes. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used to verify equivalent loading. (d) Podocytes were
transfected with either RAGE siRNA or scramble siRNA. Cells were harvested and analyzed for apoptosis by flow cytometry 24 h after
transfection. The percentage of apoptotic cells was identified with Annexin VþPI. Flow cytometry data are expressed as mean±s.d. of
three independent experiments. Analysis of variance, Po0.001, #Po0.05 vs. nonimmune IgG-treated cells or scramble siRNA-transfected
cells. (e) Podocytes were pretreated with RAGE neutralizing antibody or transfected with RAGE siRNA before AOPPs treatment. The
apoptosis of podocytes were analyzed by TUNEL assay. Representative photographs showing double immunofluorescence labeling of
Hoechst (blue) and TUNEL (green) in podocytes. (f) Co-immunoprecipitation of AOPPs and RAGE in cultured podocytes. Podocytes were
treated with AOPPs for 30min, the binding of AOPPs to RAGE was analyzed by immunoprecipitation using anti-RAGE antibody and followed
by immunoblotting using anti-AOPPs antibody. (g) Colocalization of AOPPs and RAGE in cultured podocyte cells. Podocytes were treated
with AOPPs for 30min, and then the cells were co-stained with antibodies against AOPPs (green) and RAGE (red). Nuclei were stained with
4,6-diamidino-2-phenylindole (DAPI; blue). Images were taken by confocal microscopy. Original magnification  400. AOPPs, advanced
oxidation protein products; IB, immunoblot; Ig, immunoglobulin; IP, immunoprecipitation; RAGE, receptor of advanced glycation end
products; siNC, scramble siRNA; siRNA, small interference RNA; TUNEL, terminal deoxyuridine nick-end labeling staining.
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that increased RAGE expression was mainly localized on
podocytes in AOPPs-challenged mice (Figure 5f).
Blocking RAGE attenuated AOPPs-induced podocyte
apoptosis and albuminuria in vivo
To determine the role of RAGE in AOPPs-induced podocyte
apoptosis in vivo, normal C57BL/6 mice were administrated
with intraperitoneal injection of anti-RAGE IgG at 5mg/kg
body weight or vehicle together with intravenous injection of
AOPPs-MSA for 5 weeks. We first examined podocyte
apoptosis using double-immunofluorescence labeling of
Wilms’s tumor-1 and TUNEL assay. AOPPs treatment
resulted in a significant increase of podocyte apoptosis.
Anti-RAGE treatment dramatically decreased the number of
TUNEL-positive podocytes compared with vehicle control
mice (Figure 6a and b). Likewise, AOPP-induced increase in
urinary albumin excretion was significantly attenuated by
RAGE blockade (Figure 6c).
Blocking RAGE inhibited AOPPs-induced apoptotic
signaling in vivo
Consistent with in vitro data, AOPPs-induced O2
 production
in renal cortex homogenates was blocked by anti-RAGE
IgG (Figure 7a). RAGE blockade inhibited AOPPs-induced
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Figure 2 |AOPPs-induced nicotinamide adenine dinucleotide phosphate oxidase activation and O2
 generation is RAGE-
dependent. (a) AOPPs-augmented O2
 production was inhibited by RAGE neutralizing antibody or RAGE siRNA. O2
 production in podocyte
homogenates was determined using the lucigenin chemiluminescence method. (b) Podocytes were preincubated with anti-RAGE antibody
or transfected with RAGE siRNA followed by incubation with 200 mg/ml of AOPPs-MSA for 30min. Phosphorylation of p47phox was assayed
by immunoprecipitation using anti-p47phox antibody followed by immunoblotting with antibody against phosphoserine. The interaction of
p47phox with p22phox was determined by immunoprecipitation using anti-p22phox antibody followed by immunoblotting with anti-p47phox
antibody. (c) Podocytes were preincubated with anti-RAGE antibody or transfected with RAGE siRNA followed by incubation with 200 mg/ml
of AOPPs-MSA for 12 h and then the cell lysates were harvested. The protein level of p47phox and gp91phox was analyzed by western blot.
Data are expressed as mean±s.d. of three independent experiments. Analysis of variance, Po0.001, #Po0.05 vs. IgG-treated or
scramble siRNA-transfected cells. AOPPs, advanced oxidation protein products; Ctrl, control; IB, immunoblot; Ig, immunoglobulin;
IP, immunoprecipitation; RAGE, receptor of advanced glycation end products; siNC, scramble siRNA; siRNA, small interference RNA.
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overexpression of p47phox and gp91phox in renal cortex
(Figure 7b). Similarly, AOPPs-induced activation of p53/Bax-
cleaved caspase-3 pathway was significantly inhibited by anti-
RAGE (Figure 7c). Taken together, these data demonstrated
that AOPPs-induced proapoptotic signaling in podocyte was
mediated by RAGE in vivo.
DISCUSSION
We previously demonstrated that AOPPs accumulation
resulted in podocyte apoptosis and depletion, establishing a
causative link between oxidative stress and podocyte
injury.23,26 However, the transmembrane receptor that
specifically transmits the signal of AOPPs remains unknown.
In this study, we provided in vitro and in vivo evidence that
RAGE plays a central role in AOPPs-induced podocyte
apoptosis. Blocking RAGE inhibited AOPPs-induced activa-
tion of intracellular proapoptotic pathway and protected
podocytes from apoptosis. To the best of our knowledge, this
is the first study demonstrating that AOPPs trigger podocytes
apoptosis through interaction with RAGE.
Our previous study demonstrated that accumulation of
AOPPs induce podocytes apoptosis via a cascade of signaling
events coupled with intracellular oxidative stress. AOPPs
activate NADPH oxidase through a PKC-dependent pathway,
thereby leading to an excessive generation of intracellular
superoxide, which in turn promotes the classical p53/Bax/
caspase-dependent apoptosis pathway.23 One fundamental
issue to be addressed is exactly how AOPPs transmit their
signals across the plasma membrane to elicit cellular
activities. One can assume that this probably requires a
transmembrane receptor for AOPPs. In this study, we
provided several lines of evidence demonstrating that
AOPPs-induced podocyte apoptosis is mainly mediated by
RAGE. First, AOPPs interacted with RAGE and colocalized
with RAGE in AOPPs-treated podocyte, suggesting that
AOPPs might be ligands of RAGE. Second, blocking RAGE or
knocking down the expression of RAGE significantly
protected podocyte from AOPPs-induced apoptosis both
in vitro and in vivo. Third, activation of apoptotic signaling
triggered by AOPPs was largely inhibited by RAGE blockade.
These observations support the hypothesis that activation of
RAGE is a common pathway that transduces signals from the
diverse biochemical and molecular species, leading to
propagation of inflammation and cellular perturbation.22,27
The bioactive structure of AOPPs, which interact with RAGE,
has not been defined yet and is in active study.
RAGE is a member of the IG superfamily and a
multiligand signal–transduction receptor. The advanced
glycation end products (AGEs), the first identified ligand of
RAGE, have been implicated not only in diabetes but also in
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Figure 3 |AOPPs-induced PKCa activation is RAGE-dependent. (a) AOPPs activated PKCa in cultured podocytes. Podocytes were treated
with 200mg/ml of AOPPs for indicated time period. The expression level of phosphorylated and total PKCa, PKCb1, PKCb2, and PKCz were
detected by western blot. (b) Graphic representation of the ratio of phosphorylated PKCa, PKCb1, PKCb2, and PKCz to total PKC. Data are
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induced PKCa phosphorylation was blocked by pretreatment with RAGE neutralizing antibody or RAGE siRNA transfection. (d) Graphic
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such settings as inflammation, hypoxia, and ischemia/
reperfusion injury.28,29 In addition to AGEs, RAGE interacts
with at least four other classes of ligands: the S100/
calgranulins, high-mobility group box-1, amyloid-b peptide
and other amyloid species, and Mac-1.30 These classes of
ligands are linked to diabetes, inflammation, chronic
neurodegenerative disorders, tumors, and amyloidoses.30,31
Highly intriguing is the observation that podocyte is the
principal RAGE-expressing cell in the glomerulus, with
expression also noted in the endothelium.17,32 In this study,
we found that interaction of AOPPs with RAGE triggered
podocyte apoptosis. This is consistent with Marsche et al.20,21
AOPPs AOPPs
α
-
R
AG
E
p53
a b
c
d
Bax
β-Actin
p53
Bax
β-Actin
1.2
1.5
Ctr
l
α-
RA
GE
AO
PP
s
AO
PP
s +
 Ig
G
AO
PP
s +
 α-
RA
GE Ctr
l
siR
AG
E
AO
PP
s
AO
PP
s +
 siN
C
AO
PP
s +
 siR
AG
E
1.2
1.5 p53p53
BaxBax
Pr
ot
ei
n 
ex
pr
es
sio
n 
/
ra
tio
 to
 β-
a
ct
in
 
Pr
ot
ei
n 
ex
pr
es
sio
n 
/
ra
tio
 to
 β-
a
ct
in
 
0.0
0.3
0.6
0.9
#
#
0.0
0.3
0.6
0.9
#
#
AOPPs
PARP-1 (113 kDa)
Procaspase-3
Cleaved caspase-3
PARP-1 (85 kDa)
β-Actin
4
5 1.0
Procaspase-3
Cleaved caspase-3
PARP-1 (113 kDa)
PARP-1 (85 kDa)
0.8
1.6
#
###
Pr
ot
ei
n 
ex
pr
es
sio
n 
/
ra
tio
 to
 β-
a
ct
in
Pr
ot
ei
n 
ex
pr
es
sio
n 
/
ra
tio
 to
 β-
a
ct
in
0.2
0.4
0.6
0.8
# #
#
#
0.0 0.0
Ct
rl
Ct
rl
Ct
rl
Ig
G
Ct
rl
Ig
G
α
-
R
AG
E
α
-
R
AG
E
α
-
R
AG
E
si
R
AG
E
si
R
AG
E
si
N
C
si
R
AG
E
Ct
rl
Ct
rl
Ig
G
si
R
AG
E
Ctr
l
Ctr
l
α-
RA
GE
α-
RA
GE
AO
PP
s
AO
PP
s
AO
PP
s +
 Ig
G
AO
PP
s +
 Ig
G
AO
PP
s +
 α-
RA
GE
AO
PP
s +
 α-
RA
GE
AO
PP
s +
 siR
AG
E
AO
PP
s +
 siR
AG
E
AO
PP
s +
 siN
C
AO
PP
s +
 siN
C
siR
AG
E
siR
AG
E
Figure 4 | The expression of apoptotic proteins induced by AOPPs was RAGE-dependent. Podocytes were pretreated with RAGE
neutralizing antibody or transfected with RAGE siRNA before 200 mg/ml of AOPPs stimulation for 24 h. The protein level of p53, Bax (a, b),
PARP (113 and 85 kDa), procaspase-3, and cleaved caspase-3 (c, d) was determined by western blot. Data are expressed as mean±s.d. of
three independent experiments. Analysis of variance, Po0.001, #Po0.05 vs. scramble siRNA-transfected cells. AOPPs, advanced oxidation
protein products; Ctrl, control; Ig, immunoglobulin; PARP, poly (adenosine diphosphate-ribose) polymerase; RAGE, receptor of advanced
glycation end products; siNC, scramble siRNA; siRNA, small interference RNA.
764 Kidney International (2012) 82, 759–770
or ig ina l a r t i c l e LL Zhou et al.: RAGE-mediated AOPPs-induced podocyte apoptosis
and our previous finding that AOPPs induce inflammation in
endothelial cells through interacting with RAGE.20–22 Sup-
porting our results, AGEs, via a RAGE-dependent signaling in
podocytes, lead to generation of monocyte chemoattractant
peptide-1, production of transforming growth factor-b, and
other matrix-modifying species.33,34 Pharmacological antag-
onism of RAGE or its genetic deletion imparts marked
protection from podocyte effacement, albuminuria, and
glomerular sclerosis in diseases models.34,35 These data
provide evidence linking RAGE to the pathogenesis of renal
diseases, particularly the diseases related to podocyte injury.
Although one might posit that interaction of AOPPs with
RAGE in podocyte is expected based on observation
concerning interaction of RAGE with other oxidized
proteins, this is the first study examining the interaction
of AOPPs with RAGE on kidney cells. AOPPs exert their
pathobiological effect via different receptors on renal cells.
Previous studies showed that AOPPs are capable of using
CD36, a class B transmembrane multiligand SR, for
transmitting their signals in renal tubular epithelial cells36
AOPPs can use RAGE and SR-BI for their signaling in
endothelial cells.20–22 It is noteworthy that both RAGE and
SR-BI are expressed on endothelial cells, but the expression
level of SR-BI on podocytes is very low (data not shown).
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Figure 5 |AOPPs enhanced RAGE expression in podocytes both in vitro and in vivo. AOPPs induced RAGE expression in a time- and
dose-dependent manner. Mouse podocytes were treated with indicated amount of AOPPs for 12 h (a, c), or 200 mg/ml of AOPPs for
indicated time period (b, d). The protein level of RAGE was analyzed by western blot (a, b). The mRNA level of RAGE was analyzed by real-
time PCR (c, d). Data are expressed as mean±s.d. of three independent experiments. Analysis of variance, Po0.001, *Po0.05 vs. MSA-
treated cells. (e) Western blot of RAGE expression in the kidney of control and AOPPs-treated mice. Data presented are means (n¼ 6 in each
group) ±s.d. Analysis of variance, Po0.001, *Po0.05 vs. control mice. Ctrl, mice treated with phosphate-buffered saline; AOPPs, mice
treated with AOPPs. (f) Immunohistochemistry staining analysis of RAGE localization in AOPPs-challenged mice. Renal cortex sections of
AOPPs-treated mice were paraffin-fixed and then co-stained with antibodies against Wilms’s tumor-1 (brown) and RAGE (red). AOPPs,
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Furthermore, anti-SR-BI antibody was not able to block
AOPPs-induced podocytes apoptosis, suggesting that the
receptors mediating AOPPs’ effect could be cell-type specific.
Therefore, it is important to determine in each situation the
impact of AOPPs on the affected cells, as well as the ability to
bind to cellular surface.
Although present at low levels in homeostasis, RAGE
expression is increased during disease.28,29,37 RAGE expres-
sion is upregulated in situations in which its ligands are
abundant.24,25 Immune/inflammatory disorder is another
situation in which RAGE expression is enhanced.38,39 This
study demonstrated that AOPPs accumulation upregulated
expression of RAGE in vivo and in vitro. AOPPs accumula-
tion in plasma and in renal tissue has been found in diabetic
and non-diabetic CKDs.9,11–17 Meanwhile, the upregulation
of RAGE has been demonstrated in diabetic kidney and lupus
nephropathy, particularly in podocytes.17 Therefore, the
increased activity of AOPPs–RAGE axis may promote renal
inflammation and sclerosis and thus accelerate the progres-
sion of renal diseases. Stopping the cycle of AOPPs–RAGE-
dependent stress in the glomerulus can hold significant
promise in treating renal disease of varied etiologies.
MATERIALS AND METHODS
AOPPs-MSA preparation
AOPPs-MSA were prepared in vitro by incubation of MSA (Sigma
Chemical, St Louis, MO) with hypochlorous acid (Fluke, Buchs,
Switzerland) in the absence of free amino acid/carbohydrates/lipids
to exclude the formation of AGEs-like structures as previously des-
cribed.9,23 Prepared samples were dialyzed against phosphate-buffered
saline to remove free hypochlorous acid and passed through a DetoxiGel
column (Pierce, Rockford, IL) to remove contaminated endotoxin.
Endotoxin levels in the preparation were determined with the amebocyte
lysate assay kit (Sigma, St Louis, MO) and were found to be below
0.025EU/ml. The components of AGEs, including Ne_(carboxylmethyl)
lysine, pentosidine, pyridine, or glyoxal-, glycolaldehyde-, and gly-
ceraldehyde-modified proteins were determined as described previ-
ously,22,40–44 and were found to be undetectable in the prepared samples.
RAGE and AOPPs monoclonal antibody preparation
Monoclonal antibodies against RAGE (Cloen B2-2) and AOPPs
(Clone 3F2) were generated as described previously.45,46 Briefly, the
recombinant extracellular domain (amino acid 23–342) of RAGE
protein (rhRAE) or hypochlorous acid oxidative-human albumin
were intraperitoneally injected to BALB/c mice. Mouse slenocytes
were fused with mouse myeloma cells. Only hybridoma cells that
secreted antibodies against RAGE and AOPP were cloned by
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successive limiting dilution. The ascites were purified by affinity
chromatography using HiTrap protein G Hp (GE Healthcare
Bioscience, Piscataway, NJ). The monoclonal antibody isotypes
were determined using a Monoclonal Antibody Isotype Kit (Thermo
Scientific Pierce, Rockford, IL).
The prepared monoclonal anti-RAGE antibody (B2-2) specifically
recognizes recombinant RAGE and natural RAGE expressed
on cell surface.45 We have examined the efficacy of B2-2 on blocking
AOPPs-induced reactive oxygen species production on podocytes
and macrophages. As shown in Supplementary Figure S4A and C
online, B2-2 significantly inhibited AOPPs-induced reactive oxygen
species production in a dose-dependent manner, and its efficacy was
comparable with the anti-RAGE antibody purchased from R&D
System (Minneapolis, MN; Supplementary Figure S4B and D online).
As a neutralizing antibody, B2-2 has been shown to be able to block
AGE-induced phosphorylation of moesin in endothelial cells47 and
AGE-induced CD83 expression in dendritic cells.48
Cell culture and siRNA transfection
Conditionally immortalized murine podocyte cell line was gener-
ously provided by Professor Peter Mundel (Sinai School of Medicine,
New York) and cultured as described previously.49 Experiments were
performed using passages 10 to 18, growth-restricted, conditionally
immortalized podocytes.
Oligonucleotide siRNA duplex was synthesized by Shanghai
Gene Pharma (Shanghai, China). The sequence of mouse RAGE
siRNA was 50-GGUCAGAGCUGACAGUGAUTT-30. The sequence
of scramble siRNA was 50-UUCUCCGAACGUGUCACGUTT-30.
The transfection of siRNA in podocytes was carried out with
Lipofectamine 2000 (Invitrogen, Carlsbad, CA) according to the
manufacturer’s instruction.
Animal experiment
All animal experiments were approved by the Committee on Animal
Experimentation of Southern Medical University, and performed in
compliance with the university’s Guidelines for the Care and Use of
Laboratory Animals. Twenty-four male C57BL/6 mice weighting
19–20 g were housed in a standard environment with regular light/
dark cycles and free access to water and chow diet. The animals were
randomly assigned into three groups (n¼ 6 in each group) and
received daily intravenous injection of vehicle (endotoxin-free
phosphate-buffered saline, pH 7.4), AOPPs-MSA (50mg/kg/d), or
AOPPs-MSA (50mg/kg/d) together with intraperitoneal injection of
mouse anti-RAGE monoclonal antibody (B2-2), respectively.
The RAGE antibody was dissolved in sterilized phosphate-buffered
saline and injected in a volume of 0.5ml, and was administered
in an initial bolus dose of 300 mg followed by doses of 100mg
three times weekly. The animals were killed at the end of week 5 and
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the kidneys were collected after perfusion with 25ml of ice-cold
normal saline.
Western blot and immunoprecipitation
The interaction of AOPPs-MSA with RAGE, p47phox with p22phox
and gp91phox, and phosphorylated p47phox in cultured podocytes
were determined as previously described.23,50 The goat anti-mouse
RAGE antibody was from R&D Systems, rabbit anti-mouse p22phox
goat anti-mouse gp91phox antibody, rabbit anti-mouse p47phox
antibody, rabbit anti-mouse p47phox antibody, anti-Bax mAb, anti-
Bcl-2mAb, anti-p-PKCb1 pAb (Thr-642), anti-PKCb1 pAb, anti-
PKCb2 pAb, polyclonal rabbit anti-p47phox and rabbit anti-gp91phox
were all from Santa Cruz (Santa Cruz, CA), rabbit anti-caspase-3
pAb, anti-PARP mAb, anti-PKCa pAb, anti-p-PKCz pAb (Thr-642),
and anti-PKCz mAb were all from Cell Signaling Technology
(Beverly, MA), anti-PKCa (phospho-T638) mAb, anti-p-PKCb2
pAb (phospho-T641) were from Abcam (Cambridge, MA), and
anti-p53mAb was from Oncogene (Cambridge, MA). Horseradish
peroxidase-conjugated rabbit anti-phosphoserine antibody was from
Stressgen Bioreagents (Victoria, BC, Canada) and the horseradish
peroxidase-conjugated swine anti-rabbit or goat anti-mouse or
rabbit anti-goat IgG was from Dako Cytomation (DakoCytomation,
Glostrup, Denmark).
Immunofluorescence staining and immunohistochemistry
Podocytes cultured on coverslips were fixed with cold methanol/
acetone (1:1) for 10min at 20 1C, followed by blocking with 20%
normal donkey serum in phosphate-buffered saline with anti-
AOPPs and goat anti-mouse RAGE antibody (R&D Systems)
followed by incubating with Alexa Fluor 546-conjugated donkey
anti-goat IgG and Alexa Fluor 488-conjugated chicken anti-mouse
IgG. Nuclei were stained with 4,6-diamidino-2-phenylindole (Sigma
Chemical) according to manufacturer’s instruction. Images were
taken by confocal microscopy (Leica TCS SP2 AOBS, Leica
Microsystems, Buffalo Grove, IL).
The expression of RAGE in the kidney section was determined as
described previously.17 Briefly, the sections were co-stained by anti-
RAGE (Santa Cruz) and Wilms’s tumor-1 (ab89901, Abcam,
Cambridge, UK) and then detected using the EnVision G|2
Doublestain System (Dako, Carpinteria, CA).
Real-time PCR
Total RNA was prepared using a TRIzol RNA isolation system (Life
Technologies, Grand Island, NY) according to the manufacturer’s
instruction. The first strand of complementary DNAwas synthesized
using 1 mg of RNA in 20 ml of reaction buffer using MMLV-RT and
random primers at 37 1C for 50min. Real-time PCR was performed
using a Plantinum SYBR Green qPCR SuperMix-UDG kit (Invitro-
gen). The primer sequences are as follows: mouse RAGE,
50-ACAGGCGAGGGAAGGAGGTC-30 and 50-TTTGCCATCGG-
GAATCAGAAG-30; mouse glyceraldehyde-3-phosphate dehydrogen-
ase, 50-CCAATGTGTCCGTCGTGGAT-30 and 50-TGCTGTTGAAGT
CGCAGGAG-30.
Assessment of podocyte apoptosis
Annexin V-labeled cells in cultured podocytes. Determination
of Annexin V-labeled apoptotic cells was performed as described
previously.23 Podocytes were serum starved for 24 h and pretreated
for 2 h at 37 1C with 2.5–20mg/ml of goat anti-mouse RAGE
neutralizing pAb (R&D Systems), 20 mg/ml of mouse anti-mouse
CD36 [JC63.1] blocking mAb (Abcam), 20 mg/ml of goat anti-
mouse SR class A neutralizing pAb (R&D Systems), 10 mg/ml of goat
anti-mouse LOX1 neutralizing pAb (R&D Systems), 20 mg/ml of rat
anti-mouse AGE-R3 capturing mAb (clone 202213; R&D Systems),
SR-BI (NB400-113, Novus Biologicals, Littleton, CO) or 20 mg/ml
of LEAF purified anti-mouse CD284 (TLR4) blocking antibody
(Biolegend, San Diego, CA), respectively, before incubating
with indicated amount of AOPPs-MSA for 24 h. Cells were
trypsined and double stained with fluorescein isothiocyanate-
conjugated Annexin V and propidium iodide according to the
manufacturer’s instructions (Roche, San Francisco, CA). Cells were
analyzed using a flow cytometer (BD FACS Calibur System, Franklin
Lakes, NJ).
TUNEL assay. DNA strand breaks in cultured podocytes were
identified using the in situ nick/end-labeling assay (TUNEL) as
described previously.23
NADPH-dependent superoxide (O2
) production
NADPH-dependent O2
 production by homogenates from cultured
podocytes or renal cortex was assessed by lucigenin-enhanced
chemiluminescence as described previously.23
Intracellular production of reactive oxygen species
Intracellular reactive oxygen species was detected in podocytes and
macrophages by analyzing the fluorescence intensity of the
intracellular fluoroprobe 5-(6)-chloromethyl-2 0,70-dichlorodihy-
drofluorescein diacetate (Molecular Probe, Carlsbad, CA) using a
fluorescent microplate reader at an excitation wavelength of 480nm
and an emission wavelength of 530 nm. Untreated cells were used to
determine the background fluorescence. The final fluorescent
intensity was normalized to the protein content. Data were expressed
as percentage of controls (untreated cells).
Urine albumin assay
Urine albumin was measured by using a mouse Albumin ELISA
quantitation kit, according to the manufacturer’s protocol (Bethyl
Laboratories, Montgomery, TX).
Statistical analysis
All experiments were performed in triplicate. Continuous
variables, expressed as mean±s.d., were compared using one-way
analysis of variance. Pairwise comparisons were evaluated by the
Student–Newman–Keuls procedure or Dunnett’s T3 procedure
when the assumption of equal variances did not hold. The Dunnett
procedure was used for comparisons between reference group
and other groups. Two-tailed P-value of less than 0.05 was
considered statistically significant. Statistical analyses were conducted
with SPSS 13.0, (SPSS Inc, Chicago, IL).
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SUPPLEMENTARY MATERIAL
Figure S1. Anti-RAGE antibody blocked AOPPs induced podocyte
apoptosis in a dose-dependent manner.
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Figure S2. AOPPs-induced podocytes apoptosis was not blocked by
the neutralizing antibodies against the other receptors.
Figure S3. Anti-RAGE antibody or RAGE siRNA blocked AOPPs-
induced podocytes apoptosis.
Figure S4. The efficacy of anti-RAGE neutralizing antibody (B2-2) on
blocking AOPPs-induced ROS production.
Supplementary material is linked to the online version of the paper at
http://www.nature.com/ki
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